Whether you’re a novice or someone you’ve been investing in for decades, we can all agree that this has been a wild year on Wall Street. We have seen the fastest bear market decline in history, as well as a rapid return to new heights from the all-time bear market.
But there are two important facts, all investors should understand about this market. First, every single stock market correction in history has finally (key word!) Been wiped out by a bull market rally. Secondly, we stand firmly in a new bull market. In other words, it owes itself to innovative, high-quality businesses, because unlike bear markets, the bull market is almost always measured in years, not months.
As this new bull market gets its feet, consider buying these four unstoppable stocks.
Precision medicine seems to be the hottest trend in healthcare in this decade. Instead of one-size-fits-all treatments, anything that personalizes treatment plans or improves individual convenience is going to be observed. This is why you want to be yourself Teldok Health (NYSE: TDOC).
TellDock is, as the name suggests, a cumbersome telemedicine powerhouse that has had its sales growing at an annualized annual rate of about 75% since 2013 (assuming it hits $ 1 billion in annual sales in 2020 Does). Yes, the company has benefited from the Coronovirus Disease 2019 (COVID-19) epidemic, with more tripping seizures in the second quarter. However, there was a value proposition at play long before COVID-19. This is because telemedicine visits are cheaper for health insurers than office visits, and they are more convenient for patients and physicians.
The Taildock health story was not exciting enough already, it is also in the midst of getting the applicable health signals company. Livongo Health (NASDAQ: LVGO) In an $ 18.5 billion cash-and-stock deal. Livongo collects abundant data on patients with chronic diseases and relies on artificial intelligence (AI) to send tips and elbows to its members to help them live healthy lives. Livongo has consistently doubled or nearly doubled year-over-year on diabetic member counts and is already profitable on a recurring basis, despite the US diabetes market being saturated by just over 1%.
When discussing a no-brainer investment, cyberspace should top or pass the list. As more and more businesses shift to online or remote work environments, the importance of protecting company-sensitive information is increasing. This protection is rapidly declining like cloud-centric cyber security companies Crowdstrike Holdings (NASDAQ: CRWD).
Crowdstrike’s Falcon platform is cloud-native and uses AI to assess more than 3 trillion incidents each week. Basically, the company’s platform is getting smarter at identifying threats every day. Cloudstrike customers have apparently been appreciating, as the percentage of subscribers with at least four cloud module subscriptions has expanded from 9% in fiscal Q1 2018 to 57% in FY 2014-15 – 13 quarters. Crowdstreak’s recipe is for faster margin expansion after existing customers spend more.
In terms of expansion, the company’s gross margin is already in the long-term target range of 75% to 80%. This is a result of higher margins associated with subscription-based revenue, the fact that existing customers are spending more, and CrowdStreak’s triple-digit customer growth has increased over the past three years. Crowdstrike should have little trouble doubling sales twice this decade.
Have I mentioned the importance of precision medicine?
There are major stocks within a specific industry, and then there is Spontaneous surgical (NASDAQ: ISRG) In the supportive surgical space. The company has installed 5,865 of its Da Vinci surgical systems worldwide over the past 20 years. This is more than any of its competitors on a combined basis. What’s more, some deep-pocketed contestants have gone into snags before the launch of competing systems. Sahaj Surgical has had 20 years to build a relationship with the medical community, and its competitive advantage is almost impossible.
Additionally, the company’s operating margin is designed to improve over time. During the 2000s, the lion’s share of the company’s revenue was derived from selling its value to the Da Vinci system. The problem is that these systems are complex and expensive, meaning that the margin is not as great. However, we have seen equipment and accessories sold with each process and service revenue in recent years. These are significantly higher margin operating segments. During the first nine months of FY 2020, these high-margin revenue channels accounted for 73.2% of total sales.
As time passes, the increase in income of the Interactive should not be disturbed by the increase in its sales.
Yes, I just went ahead and included an electric utility stock among a list of fast growing companies that you would like to own for the new bull market. As you are about to see, Next energy (NYSE: NEE) Teladoc is every bit as ageless as CrowdStrike and Spontaneous Surgical.
What makes NextEra so special is the desire to innovate the company. No electric utility is generating more capacity from solar or wind power than Next Ira. While the cost of upgrading its power-generating capacity to renewable capacity is not cheap, the reward is very beneficial. NextEra’s electricity generation costs have sunk over time, and its compound annual growth rate has consistently averaged in the high single digits over the past decade. If Capitol Hill ever meets clean-energy requirements for our nation’s utilities, NextEra Energy will be ahead of the curve.
For the company’s traditional utility operations (ie, non-renewable energy), they are regulated. This is a great way to say that NextEra cannot pass along a price increase at any time, but instead requires OK from state public utility commissions. While this may sound like a hindrance, it really isn’t. This ensures that NextEra does not compete with potentially volatile wholesale electricity pricing, and greatly approximates the company’s cash flow.